Results 31 to 40 of about 34,959 (356)

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up

Научно-практическая ревматология, 2023
Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods.
S. V. Gavrisheva, D. T. Abdurakhmanov, N. M. Bulanov, E. L. Tanashhuk, T. P. Rozina, E. N. Nikulkina, S. Yu. Milovanova, E. A. Nabatchikova, A. L. Filatova, E. E. Starostina, T. N. Krasnova, S. V. Moiseev   +11 more
doaj   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]

Farmacia Hospitalaria, 2016
Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis, Javier Saez de la Fuente, Ismael Escobar Rodriguez, Concepción Esteban Alba, Ana Such Díaz, Ismael Escobar Rodríguez   +5 more
doaj   +1 more source

Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]

, 2017
BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Farinati, Fabio, Ferrarese, Alberto, Forton, Dm, Franceschet, E, Gambato, M, Germani, Giacomo, Mescoli, Claudia, Romano, Antonietta, Rugge, Massimo, Russo, FRANCESCO PAOLO, Senzolo, Marco, Shalaby, S, Vitale, A, Zanetto, Alberto   +16 more
core   +1 more source

Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience

Annals of Hepatology, 2019
Introduction and aim: Recurrent HCV infection after liver transplant (LT) has a negative impact on graft and patient survival. The aim of this study is to describe the efficacy and safety of sofosbuvir (SOF-based) regimens in the treatment of recurrent ...
Alexandre Araujo, Vanessa Valenzuela-Granados, Antonio B. Lopes, Matheus T. Michalczuk, Augusto Mantovani, Mario R. Alvares-da-Silva   +5 more
doaj   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients

Nefrología (English Edition), 2017
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez   +9 more
doaj   +1 more source

Chronic Hepatitis C Treatment with New Antiviral Agents

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed.
Özlem KANDEMİR
doaj   +1 more source

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources